VJHemOnc is committed to improving our service to you

EHA 2019 | lymphoma: REGN197

VJHemOnc is committed to improving our service to you

Rajat Bannerji

REGN197 has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. Rajat Bannerji, MD, PhD, Rutgers Cancer institute of New Jersey, NJ, discusses this at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter